Treatment outcome and prognostic factors for patients with bone-only metastases of breast cancer: A single-institution retrospective analysis

Oncologist

Volumn 16, Issue 2, 2011, Pages 155-164

  Niikura, Naoki ^a,b   Liu, Jun ^a   Hayashi, Naoki ^a   Palla, Shana L ^a   Tokuda, Yutaka ^b   Hortobagyi, Gabriel N ^a   Ueno, Naoto T ^a   Theriault, Richard L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bone metastases; Breast cancer; Prognostic factor

Indexed keywords

ANTHRACYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; IMATINIB; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; ARTICLE; ASYMPTOMATIC DISEASE; BONE METASTASIS; BREAST CANCER; CANCER HORMONE THERAPY; CANCER SURVIVAL; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79952609466     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0350     Document Type: Article

References (26)

1. Manders K, van de Poll-Franse LV, Creemers GJ et al. Clinical management of women with metastatic breast cancer: A descriptive study according to age group. BMC Cancer 2006;6:179.
2. Smalley RV, Scogna DM, Malmud LS. Advanced breast cancer with boneonly metastases: A chemotherapeutically responsive pattern of metastases. Am J Clin Oncol 1982;5:161-166.
3. Swenerton KD, Legha SS, Smith T et al. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 1979; 39:1552-1562.
4. Sherry MM, Greco FA, Johnson DH et al. Metastatic breast cancer confined to the skeletal system. An indolent disease. Am J Med 1986;81: 381-386.
5. Sherry MM, Greco FA, Johnson DH et al. Breast cancer with skeletal metastases at initial diagnosis. Distinctive clinical characteristics and favorable prognosis. Cancer 1986;58:178-182.
6. Scheid V, Buzdar AU, Smith TL et al. Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy. Cancer 1986;58:2589-2593.
7. Chiedozi LC. Prognostic significance of exclusive skeletal metastases in stage IV primary carcinoma of the breast. Surg Gynecol Obstet 1988;167: 303-306.
8. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987;55:61-66.
9. Plunkett TA, Smith P, Rubens RD. Risk of complications from bone metastases in breast cancer: Implications for management. Eur J Cancer 2000;36:476-482.
10. Domchek SM, Younger J, Finkelstein DM et al. Predictors of skeletal complicationsin patients ith metastatic breast carcinoma. Cancer 2000;89: 363-368.
11. Perez JE, Machiavelli M, Leone BA et al. Bone-only versus visceral-only metastatic pattern in breast cancer: Analysis of 150 patients. A GOCS study. Grupo Oncologico Cooperativo del Sur. Am J Clin Oncol 1990;13: 294-298.
12. Coleman RE, Smith P, Rubens RD. Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer 1998;77:336-340.
13. Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998;339:974-984.
14. Singletary SE, Allred C, Ashley P et al. Staging system for breast cancer: Revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am 2003;83:803-819.
15. Black MM, Speer FD. Nuclear structure in cancer tissues. Surg Gynecol Obstet 1957;105:97-102.
16. The World Health Organization. Histological typing of breast tumors. Neoplasma 1983;30:113-123.
17. Cazzaniga ME, Dogliotti L, Cascinu S et al. Diagnosis, management and clinical outcome of bone metastases in breast cancer patients: Results from a prospective, multicenter study. Oncology 2006;71: 374-381.
18. Koizumi M, Yoshimoto M, Kasumi F et al. Comparison between solitary and multiple skeletal metastatic lesions of breast cancer patients. Ann Oncol 2003;14: 1234-1240.
19. Major PP, Cook RJ, Lipton A et al. Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. BMC Cancer 2009;9: 272.
20. Vredenburgh JJ, Madan B, Coniglio D et al. A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy andautologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy. Bone Marrow Transplant 2006;37:1009-1015.
21. Ueno NT, de Souza JA, Booser D et al. Pilot study of targeted skeletal radiation therapy for bone-only metastatic breast cancer. Clin Breast Cancer 2009;9:173-177.
22. Esteva FJ, Valero V, Booser D et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:1800-1808.
23. Tokuda Y, Suzuki Y, Ohta M et al. Compassionate use of humanized anti-HER2/neu protein, trastuzumab for metastatic breast cancer in Japan. Breast Cancer 2001;8:310-315.
24. Hortobagyi GN. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. Semin Oncol 2001;28(suppl 18):43-47.
25. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
26. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-2648.